| Literature DB >> 35232476 |
Leonard Seng1, Aaron Drovandi1, Malindu E Fernando1,2,3, Jonathan Golledge4,5,6.
Abstract
BACKGROUND: There is a lack of high quality evidence to guide the optimal management of diabetes-related foot infection, particularly in cases of severe diabetes-related foot infection and diabetes-related foot osteomyelitis. This study examined the opinions of surgeons about the preferred management of severe diabetes-related foot infection.Entities:
Keywords: Clinical practice; Diabetic foot disease; Orthopaedic surgery; Survey; Vascular surgery
Mesh:
Year: 2022 PMID: 35232476 PMCID: PMC8889647 DOI: 10.1186/s13047-022-00523-w
Source DB: PubMed Journal: J Foot Ankle Res ISSN: 1757-1146 Impact factor: 2.303
Characteristics of the forty nine participants
| Surgical specialty | 29 (59.2%) |
|---|---|
Queensland New South Wales South Australia Tasmania Victoria Western Australia Australian Capital Territory New Zealand | 29 (59.2%) 5 (10.2%) 2 (4.1%) 1 (2.0%) 4 (8.2%) 3 (6.1%) 2 (4.1%) 3 (6.1%) |
Public hospital Private practice | 31 (63.3%) 18 (36.7%) |
| 27.0 (9.4) | |
RACS accredited Consultant Others | 46 (93.9%) 3 (6.1%) |
Data presented as number (%) and mean (standard deviation). RACS = Royal Australasian College of Surgeons
Current management practices
| Total | Vascular surgeons | Orthopaedic surgeons | p-value | |
|---|---|---|---|---|
| Based on international classification system | 13/49 (26.5%) | 9/29 (31.0%) | 4/20 (20.0%) | 2 |
| Based on extent of erythema | 27/49 (55.1%) | 18/29 (62.1%) | 9/20 (45.0%) | |
| Based on extent of skin with raised temps | 19/49 (38.8%) | 14/29 (48.3%) | 5/20 (25.0%) | |
| Based on amount and type of wound exudate | 21/49 (42.9%) | 14/29 (48.3%) | 7/20 (35.0%) | |
| Based on extent of swelling | 20/49 (40.8%) | 15/29 (51.7%) | 5/20 (25.0%) | |
| Based on degree of tissue necrosis | 30/49 (61.2%) | 19/29 (65.5%) | 11/20 (55.0%) | |
| Others | 18/49 (36.7%) | 6/29 (20.7%) | 12/20 (60.0%) | |
| Tissue or bone biopsy | 17/49 (34.7%) | 4/29 (13.8%) | 13/20 (65.0%) | |
| Wound swab | 27/49 (55.1%) | 22/29 (75.9%) | 5/20 (25.0%) | |
| Others | 5/49 (10.2%) | 3/29 (10.3%) | 2/20 (10.0%) | |
| Yes | 14/49 (28.6%) | 10/29 (34.5%) | 4/20 (7.4%) | |
| No | 35/49 (71.4%) | 19/29 (65.5%) | 16/20 (29.6%) | |
| Piperacillin/Tazobactam | 21/41 (51.2%) | 13/22 (59.1%) | 8/19 (42.1%) | |
| Amoxicillin/Clavulanic acid | 8/41 (19.5%) | 4/22 (18.2%) | 4/19 (21.1%) | |
| Cefazolin | 5/41 (12.2%) | 2/22 (9.1%) | 3/19 (15.8%) | |
| Defer to guidelines or infectious diseases | 5/41 (12.2%) | 2/22 (9.1%) | 3/19 (15.8%) | |
| Other antibiotics | 2/41 (4.9%) | 1/22 (4.5%) | 1/19 (5.3%) | |
| IV | 31/40 (77.5%) | 18/21 (85.7%) | 13/19 (68.4%) | |
| IV + Oral | 2/40 (5.0%) | 1/21 (4.8%) | 1/19 (5.3%) | |
| Defer to guidelines or infectious diseases physicians | 5/40 (12.5%) | 2/21 (9.5%) | 3/19 (15.8%) | |
| Others | 2/40 (5.0%) | 0/21 (0.0%) | 2/19 (10.5%) | |
| Iodine-based dressings | 26/42 (61.9%) | 14/22 (63.6%) | 12/20 (60.0%) | 2 |
| Betadine paint | 10/42 (23.8%) | 9/22 (40.9%) | 1/20 (5.0%) | |
| Saline soaked packing | 19/42 (45.2%) | 12/22 (54.5%) | 7/20 (35.0%) | |
| Betadine soaked packing | 13/42 (31.0%) | 10/22 (45.5%) | 3/20 (15.0%) | |
| Chlorohexidine-based dressings | 1/42 (2.4%) | 0/22 (0.0%) | 1/20 (5.0%) | |
| Silver-based dressings | 23/42 (54.8%) | 11/22 (50.0%) | 12/20 (60.0%) | |
| Honey-based dressings | 1/42 (2.4%) | 0/22 (0.0%) | 1/20 (5.0%) | |
| Negative pressure therapy | 38/42 (90.5%) | 19/22 (86.4%) | 19/20 (95.0%) | |
| No dressing | 2/42 (4.8%) | 2/22 (9.1%) | 0/20 (0.0%) | |
| Others | 9/42 (21.4%) | 8/22 (36.4%) | 1/20 (5.0%) | |
| Healing by primary closure | 19/42 (45.2%) | 10/22 (45.5%) | 9/20 (45.0%) | 2 |
| Healing by delayed primary closure | 27/42 (64.3%) | 13/22 (59.1%) | 14/20 (70.0%) | |
| Superficial skin graft | 18/42 (42.9%) | 13/22 (59.1%) | 5/20 (25.0%) | |
| Healing by secondary intention | 39/42 (92.9%) | 20/22 (90.9%) | 19/20 (95.0%) | |
1% do not add up to 100% as participants could select multiple responses, 2 As responders could indicate a positive response to more than one option statistical testing was not possible due to the dependence of responses, 3 Fisher-Freeman-Halton test, 4 Yates continuity correction
Additional areas to be covered in guidelines
| Additional areas to be covered in guidelines | n |
|---|---|
Treatment-based decisions • • • • • | 9 |
Holistic management • • • • | 7 |
Local resource consideration • • | 2 |
Opinions of managing diabetes-related foot infection and osteomyelitis
| Total | Vascular surgeons | Orthopaedic surgeons | ||
|---|---|---|---|---|
| Probe-to-bone test | 35/49 4 (3–5) | 19/29 4 (3–5) | 16/20 3 (2–4) | |
| Bone biopsy | 35/49 3 (2–5) | 18/29 3 (2–4) | 17/20 4 (2–5) | |
| Plain x-ray | 40/49 3 (2–4) | 22/29 3 (2–4) | 18/20 3.5 (2–4) | |
| Magnetic resonance imaging | 39/49 4 (3–5) | 21/29 4 (3.5–5) | 18/20 4 (3–5) | |
| Bone scan | 24/49 3 (2–4) | 12/29 3 (2–4) | 12/20 3 (2–3.75) | |
| PET-CT scan | 19/49 3 (3–4) | 10/29 3 (2.75–4) | 9/20 4 (3–4) | |
| Wound dressing choice | 40/49 4 (3.25–5) | 21/29 5 (4–5) | 19/20 4 (3–4) | |
| Antibiotic choice | 39/49 4 (4–5) | 21/29 4 (4–5) | 18/20 4 (3–4) | |
| Antibiotic duration | 40/49 4 (3–4) | 22/29 3.5 (3–4) | 18/20 4 (3–4) | |
| Indications for removal of infected bone | 41/49 4 (4–5) | 22/29 4.5 (4–5) | 19/20 4 (4–5) | |
| Indications for surgical debridement | 42/49 5 (4–5) | 22/29 5 (4–5) | 20/20 4 (4–5) | |
| Extent of surgical debridement | 42/49 4 (4–5) | 22/29 5 (4–5) | 20/20 4 (4–5) | |
| Wound dressing choice | 41/49 4 (3–5) | 21/29 4 (3.5–5) | 20/20 4 (3–4) | |
| Antibiotic choice | 40/49 3 (2–4) | 21/29 3 (2–3.5) | 19/20 3 (2–4) | |
| Antibiotic duration | 40/49 3 (2–3.75) | 21/29 3 (3–4) | 19/20 3 (2–4) | |
| Indications for removal of infected bone | 38/49 3 (3–4) | 19/29 3 (2–3) | 19/20 3 (2–4) | |
| Indications for surgical debridement | 38/49 3 (2–4) | 20/29 3 (2–4) | 18/20 3 (2–4) | |
| Extent of surgical debridement | 41/49 3 (2–4) | 21/29 3 (2–4) | 20/20 3 (2–4) | |
| Wound dressing choice | 31/49 4 (3–4) | 16/29 4 (3–5) | 15/20 3 (3–4) | |
| Antibiotic choice | 33/49 3 (2–4) | 18/29 3 (2–4) | 15/20 3 (2–4) | |
| Antibiotic duration | 35/49 4 (3–4) | 18/29 4 (3–4) | 17/20 4 (2.5–4) | |
| Indications for removal of infected bone | 34/49 4 (3–5) | 17/29 4 (3–5) | 17/20 4 (2.5–5) | |
| Indications for surgical debridement | 32/49 4 (2–5) | 14/29 4 (2–4.25) | 18/20 4 (2.75–5) | |
| Extent of surgical debridement | 34/49 4 (2.75–4.25) | 16/29 4 (3–4.75) | 18/20 4 (2–4.25) | |
1 Reported as median (IQR), 2 Mann-Whitney U test
Revascularisation decisions
| Revascularisation decision | Total | Vascular surgery | Orthopaedic surgery |
|---|---|---|---|
Severity of ischemia determined via: • Toe pressures/ABI 1 • Palpation of foot/lower limb pulses • Imaging modalities • Wound healing & appearance | 23/33 (69.7%) | 18/18 (100.0%) | 5/15 (33.3%) |
| Referral to vascular surgery | 10/33 (30.3%) | 0/18 (0%) | 10/15 (66.7%) |
1 ABI = Ankle brachial pressure index